824 filings
8-K
SNGX
Soligenix Inc
31 May 24
Soligenix Announces Reverse Stock Split
8:00am
DEFA14A
SNGX
Soligenix Inc
29 May 24
Additional proxy soliciting materials
4:05pm
DEFA14A
SNGX
Soligenix Inc
28 May 24
Additional proxy soliciting materials
4:08pm
8-K
SNGX
Soligenix Inc
24 May 24
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
4:05pm
DEFA14A
SNGX
Soligenix Inc
22 May 24
Additional proxy soliciting materials
4:05pm
8-K
hlih7qxho59 v4ol
17 May 24
Other Events
4:25pm
DEFA14A
0s7f63woncc1v5cibc
17 May 24
Additional proxy soliciting materials
4:09pm
DEFA14A
56g72qi74i i18m
15 May 24
Additional proxy soliciting materials
4:05pm
424B3
ug7vxy
10 May 24
Prospectus supplement
4:16pm
ARS
g6d5zb
29 Apr 24
Annual report to shareholders
4:03pm
8-K
ptauqv26h85pg7yv6
22 Apr 24
Soligenix Announces Pricing of $4.75 Million Public Offering
4:05pm
424B4
klnk5tlnb
19 Apr 24
Prospectus supplement with pricing info
4:05pm
EFFECT
oztjrz hrbcz9w7r0
17 Apr 24
Notice of effectiveness
12:15am
8-K
5fx5kd
3 Apr 24
Randomized Study with 18 Weeks Continuous Treatment Expected to Replicate and Extend Results from the First, Statistically Significant Phase 3 Study
4:05pm